R) Reported to Be Safe and Effective in Study Published in European Journal of...XclairCentre Daily Times: 5 views since Monday, July 7, 2008 at 09:35 AMALIGN Pharmaceuticals, LLC, a wholly owned subsidiary of Cyclacel Pharmaceuticals, Inc., (NASDAQ: CYCC, CYCCP) announced results of a double-blinded, randomized, vehicle-controlled clinical study showing that Xclair(R) cream (formerly MAS065D) is safe and effective in the treatment and prevention of radiation dermatitis. These results were published in the May-June 2008 issue of the European ...
Published in: Randomized Things